-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ISM-001 in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ISM-001 in Idiopathic Pulmonary Fibrosis Drug Details:ISM-001055 is under development for the treatment of idiopathic pulmonary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INS-08055 in Idiopathic Pulmonary Fibrosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. INS-08055 in Idiopathic Pulmonary Fibrosis Drug Details: INS-08055 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Povorcitinib Phosphate in Vitiligo
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Povorcitinib Phosphate in Vitiligo Drug Details: Povorcitinib (INCB-54707) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Amyotrophic Lateral Sclerosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DNL-788 in Amyotrophic Lateral Sclerosis Drug Details:DNL-788 is under development for the treatment of Alzheimer’s disease,...
-
Sector Analysis
![]()
Artificial Intelligence in Pharma – Impact, Trends, Key Players and Top AI Drugs
This report investigates the impacts and development of Artificial Intelligence within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
-
Thematic Analysis
New![]()
Digital Transformation and Emerging Technologies in the Healthcare Industry – Thematic Intelligence
Explore trends and insights from the following data in our ‘Digital Transformation and Emerging Technologies in the Healthcare Industry’ report: Stay up to date on the scope, challenges, and essentials for the digital transformation within the healthcare industry. Explore how innovations are transforming the healthcare industry and what impact on the sector these technologies will have soon. Develop and design your corporate strategies through an in-house expert analysis of the key factors of digital transformation and emerging technology in the healthcare sector....
-
Analyst Opinions
![]()
New Prescription – Generative Artificial Intelligence (AI) Meets Healthcare
Generative Artificial Intelligence (AI) in Healthcare Report Overview Generative AI can accelerate pharmaceutical drug discovery, enhance clinical trials and drug approval, optimize manufacturing and the supply chain, boost sales and marketing, and improve healthcare delivery as well as patient outcomes. For instance, pharmaceutical drug discovery can be enhanced by automating target identification and optimizing lead generation, significantly reducing the time and resources required in drug development. Furthermore, Generative AI enhances clinical trials by facilitating the eligibility screening process, enrollment, predicting outcomes,...
-
Company Insights
![]()
Boehringer Ingelheim – Digital Transformation Strategies
Boehringer Digital Transformation Strategies Report Overview Boehringer Ingelheim (Boehringer) is tapping into key disruptive technologies including AI, big data, digital therapeutics, and cloud, among others to enhance its operational efficiency and product offerings. The annual ICT spending of Boehringer is estimated at $1.0 billion for 2022. A major share of this spending is earmarked for acquiring software, ICT services and hardware from vendors. Boehringer is a family-owned pharmaceutical company engaged in the discovery, development, manufacture, and marketing of human pharmaceuticals...
-
Thematic Analysis
![]()
Generative Artificial Intelligence (AI) in Defense – Thematic Intelligence
Access and explore in-depth trends and insights in our ‘Generative Artificial Intelligence (AI) in Defense’ report: Explore investment opportunities for armed forces, suppliers, and institutional investors, across the emerging generative AI value chain. Highlights from the range of different generative AI research and development initiatives currently being undertaken by various military organizations and defense companies. Studies of emerging technological trends and their broader impact on the defense market. How is the 'Generative Artificial Intelligence (AI) in Defense' report different from...
-
Analyst Opinions
![]()
ChatGPT Trailblazers – How Startups Democratize Generative Artificial Intelligence (AI)
Accessing in-depth insights from the ‘ChatGPT Trailblazers - Generative AI Startups’ report will allow you to: Gain an understanding on the budding startup ecosystem in generative AI with a focus on their products and venture capital activity. Delve into the dynamic application landscape of generative AI, highlighting generative AI solutions and their disruptive potential. Leverage on valuable insights into this burgeoning field that aids industry stakeholders in identifying promising generative AI startups and understanding the implications of their technologies on...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.